{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:13:34Z","timestamp":1775808814338,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"H2020","doi-asserted-by":"publisher","award":["Centro-01-0145-FEDER-000019-C4-Centro de Compet\u00eancias em Cloud Computing"],"award-info":[{"award-number":["Centro-01-0145-FEDER-000019-C4-Centro de Compet\u00eancias em Cloud Computing"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00709\/2020"],"award-info":[{"award-number":["UIDB\/00709\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Psilocybin is a naturally occurring tryptamine known for its psychedelic properties. Recent research indicates that psilocybin may constitute a valid approach to treat depression and anxiety associated to life-threatening diseases. The aim of this work was to perform a systematic review with meta-analysis of clinical trials to assess the therapeutic effects and safety of psilocybin on those medical conditions. The Beck Depression Inventory (BDI) was used to measure the effects in depression and the State-Trait Anxiety Inventory (STAI) was used to measure the effects in anxiety. For BDI, 11 effect sizes were considered (92 patients) and the intervention group was significantly favored (WMD = \u22124.589; 95% CI = \u22124.207 to \u22120.971; p-value = 0.002). For STAI-Trait, 11 effect sizes were considered (92 patients), being the intervention group significantly favored when compared to the control group (WMD = \u22125.906; 95% CI = \u22127.852 to \u22123.960; p-value \u02c2 0.001). For STAI-State, 9 effect sizes were considered (41 patients) and the intervention group was significantly favored (WMD = \u22126.032; 95% CI = \u22128.900 to \u22123.164; p-value \u02c2 0.001). The obtained results are promising and emphasize the importance of psilocybin translational research in the management of symptoms of depression and anxiety, since the compound may be effective in reducing symptoms of depression and anxiety in conditions that are either resistant to conventional pharmacotherapy or for which pharmacologic treatment is not yet approved. Moreover, it may be also relevant for first-line treatment, given its safety.<\/jats:p>","DOI":"10.3390\/biomedicines8090331","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T23:12:49Z","timestamp":1599433969000},"page":"331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases\u2014A Systematic Review and Meta-Analysis of Clinical Trials"],"prefix":"10.3390","volume":"8","author":[{"given":"Ana Sofia","family":"Vargas","sequence":"first","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-6522","authenticated-orcid":false,"given":"\u00c2ngelo","family":"Lu\u00eds","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"},{"name":"Grupo de Revis\u00f5es Sistem\u00e1ticas (GRUBI), Faculdade de Ci\u00eancias da Sa\u00fade, Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"},{"name":"Laborat\u00f3rio de F\u00e1rmaco-Toxicologia, UBIMedical, Universidade da Beira Interior, Estrada Municipal 506, 6200-284 Covilh\u00e3, Portugal"}]},{"given":"M\u00e1rio","family":"Barroso","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Qu\u00edmica e Toxicologia Forenses, Instituto Nacional de Medicina Legal e Ci\u00eancias Forenses, I.P.\u2014Delega\u00e7\u00e3o do Sul, Rua Manuel Bento de Sousa, 3, 1150-219 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-8998","authenticated-orcid":false,"given":"Eugenia","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o em Ci\u00eancias da Sa\u00fade (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"},{"name":"Laborat\u00f3rio de F\u00e1rmaco-Toxicologia, UBIMedical, Universidade da Beira Interior, Estrada Municipal 506, 6200-284 Covilh\u00e3, Portugal"}]},{"given":"Lu\u00edsa","family":"Pereira","sequence":"additional","affiliation":[{"name":"Grupo de Revis\u00f5es Sistem\u00e1ticas (GRUBI), Faculdade de Ci\u00eancias da Sa\u00fade, Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilh\u00e3, Portugal"},{"name":"Centro de Matem\u00e1tica e Aplica\u00e7\u00f5es (CMA-UBI), Universidade da Beira Interior, Rua Marqu\u00eas d\u2019\u00c1vila e Bolama, 6201-001 Covilh\u00e3, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neubiorev.2017.08.019","article-title":"Treatment resistant depression: A multi-scale, systems biology approach","volume":"84","author":"Akil","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0885-3924(00)00249-9","article-title":"The changeable nature of patients\u2019 fears regarding chemotherapy: Implications for palliative care","volume":"21","author":"Passik","year":"2001","journal-title":"J. Pain Symptom Manag."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-006-9447-x","article-title":"Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients","volume":"105","author":"Groenvold","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1017\/S0033291709992285","article-title":"Depression and cancer mortality: A meta-analysis","volume":"40","author":"Pinquart","year":"2010","journal-title":"Psychol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.12688\/f1000research.11902.1","article-title":"Advancing psychosocial care in cancer patients","volume":"6","author":"Grassi","year":"2017","journal-title":"F1000Research"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1200\/JOP.2015.008508","article-title":"Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment","volume":"12","author":"Freedman","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_9","unstructured":"Orhurhu, V.J., Claus, L.E., and Cohen, S.P. (2019). Ketamine Toxicity, StatPearls Publishing."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"112749","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1002\/acr.20561","article-title":"Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A)","volume":"63","author":"Julian","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_15","unstructured":"Ryan, R., Hill, S., Prictor, M., and McKenzie, J. (2020, February 08). Cochrane Consumers & Communication Review Group Study Quality Guide Guide for Review Authors on Assessing Study Quality. Available online: https:\/\/cccrg.cochrane.org\/sites\/cccrg.cochrane.org\/files\/public\/uploads\/StudyQualityGuide_May%202013.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Borenstein, M., Hedges, L., and Higgins, J. (2009). Introduction to Meta-Analysis, John Wiley & Sons.","DOI":"10.1002\/9780470743386"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","article-title":"Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression","volume":"235","author":"Stroud","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3389\/fpsyg.2018.01721","article-title":"More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression","volume":"9","author":"Lyons","year":"2018","journal-title":"Front. Psychol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Bolstridge","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_24","first-page":"619","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Bolstridge","year":"2016","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Erritzoe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers","volume":"78","author":"Kraehenmann","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nrn2345","article-title":"Cognitive therapy versus medication for depression: Treatment outcomes and neural mechanisms","volume":"9","author":"DeRubeis","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1176\/appi.ajp.159.3.419","article-title":"Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims","volume":"159","author":"Pandey","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1001\/jama.284.22.2907","article-title":"Depression, Hopelessness, and Desire for Hastened Death in Terminally Ill Patients With Cancer","volume":"284","author":"Breitbart","year":"2000","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological affects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0022167817715966","article-title":"Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress","volume":"57","author":"Swift","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as Medicines: An Emerging New Paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1098\/rstb.1998.0341","article-title":"The neural correlates of consciousness: An analysis of cognitive skill learning","volume":"353","author":"Raichle","year":"1998","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00408109","article-title":"Comparison of the reactions induced by psilocybin and LSD-25 in man","volume":"1","author":"Isbell","year":"1959","journal-title":"Psychopharmacologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2045125312451270","article-title":"Hallucinogen-persisting perception disorder","volume":"2","author":"Hermle","year":"2012","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Studerus, E., Gamma, A., Kometer, M., and Vollenweider, F.X. (2012). Prediction of psilocybin response in healthy volunteers. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030800"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: Guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin\u2014Summary of knowledge and new perspectives","volume":"24","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neropharmacology"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/8\/9\/331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:07:05Z","timestamp":1760177225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/8\/9\/331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,5]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["biomedicines8090331"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines8090331","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,5]]}}}